{"id":"NCT02496767","sponsor":"Cytokinetics","briefTitle":"Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year","officialTitle":"A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-03","primaryCompletion":"2017-03-09","completion":"2017-09-27","firstPosted":"2015-07-14","resultsPosted":"2020-06-19","lastUpdate":"2020-09-09"},"enrollment":744,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"Tirasemtiv","otherNames":["CK-2017357"]},{"type":"DRUG","name":"Placebo tablets","otherNames":[]}],"arms":[{"label":"Group 1 - Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Group 2 - 250 mg tirasemtiv","type":"EXPERIMENTAL"},{"label":"Group 3 - 375 mg tirasemtiv","type":"EXPERIMENTAL"},{"label":"Group 4 - 500 mg tirasemtiv","type":"EXPERIMENTAL"}],"summary":"This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.","primaryOutcome":{"measure":"Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)","timeFrame":"24 weeks","effectByArm":[{"arm":"Double-blind, Placebo-controlled: Group 1 - Placebo","deltaMin":-14.354,"sd":1.227},{"arm":"Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv","deltaMin":-12.648,"sd":1.5165},{"arm":"Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv","deltaMin":-13.742,"sd":1.6076},{"arm":"Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv","deltaMin":-13.927,"sd":1.7213}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3782"},{"comp":"OG000 vs OG002","p":"0.7625"},{"comp":"OG000 vs OG003","p":"0.8394"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":81,"countries":["United States","Belgium","Canada","France","Germany","Ireland","Italy","Netherlands","Portugal","Spain","United Kingdom"]},"refs":{"pmids":["39513379","29402141"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":744},"commonTop":["Dizziness","Fatigue","Muscular weakness","Weight decreased","Nausea"]}}